A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations  

作　　者：Pingli Wang Liming Cao Panwen Tian Shengxiang Ren Liyun Miao Chengzhi Zhou Yun Fan Yuping Li Dongqing Lv Xin Zhao Mei Yang Chaonan Zhu Bing Yu June Xu Yong Song Kai Wang 

机构地区：[1]Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,P. R. China [2]Department of Respiratory Medicine,Xiangya Hospital Central South University,Changsha,Hunan,P. R. China [3]Department of Respiratory and Critical Care Medicine,West China Hospital of Sichuan University,Chengdu,Sichuan,P. R. China [4]Department of Medical Oncology,Shanghai Pulmonary Hospital,Shanghai,P. R. China [5]Department of Respiratory Medicine,The Affiliated Drum Tower Hospital of Nanjing University Medical School,Nanjing,Jiangsu,P. R. China [6]Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,P. R. China [7]Department of Medical Thoracic Oncology,Cancer Hospital of University of Chinese Academy of Sciences,Hangzhou,Zhejiang,P. R. China [8]Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,P. R. China [9]Department of Respiratory Medicine,Taizhou Hospital of Zhejiang Province,Taizhou,Zhejiang,P. R. China [10]Department of Respiratory and Critical Care Medicine,Jiangsu Province Hospital,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,P. R. China [11]Huadong Global Development Center,Hangzhou ZhongMei HuaDong Pharmaceutical Company,Hangzhou,Zhejiang,P. R. China [12]Department of Respiratory Medicine,General Hospital of Eastern Theater Command,Nanjing,Jiangsu,P. R. China [13]Correspondenc [14]Kai Wang,Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,Zhejiang,P. R. China. [15]Yong Song,Department of Respiratory Medicine,General Hospital of Eastern Theater Command,Nanjing 350025,Jiangsu,P. R. China. [16]Department of Respiratory and Critical Care Medicine,The Fourth Affiliated Hospital of Zhejiang University School of Medicine,Yiwu,Zhejiang,P. R. China

出　　处：《Cancer Communications》2023年第9期1059-1063,共5页癌症通讯（英文）

基　　金：Hangzhou Zhongmei Huadong Pharmaceutical Company。

摘　　要：Dear Editor,Uncommon mutations in exons 18-21 of the epidermal growth factor receptor(EGFR)gene account for 10%–15%of all EGFR mutations when considered as a whole group[1,2].However,each variant confers heterogeneous clinical outcomes to different generations of EGFR tyrosine kinase inhibitors(TKIs)with G719X,L861Q,and/or S768I showing adequate sensitivity to EGFR inhibition[1–3].Osimertinib,based on its superior survival outcomes,has become the preferred first-line treatment for patients diagnosed with advanced non-small cell lung cancer(NSCLC)harboring common EGFR mutations[4];however,its efficacy in patients harboring G719X,S768I,and/or L861Q mutations was comparable or even inferior to Afatinib[5].Afatinib,a second-generation EGFR-TKI,has received approval for extended clinical indication in treating previously untreated patients with metastatic NSCLC harboring G719X,L861Q,and/or S768I based on the findings from the pooled analysis of three clinical trials(LUX-Lung 2/3/6)[2].The real-world clinical efficacy of Afatinib for treating this patient subset has been consistently demonstrated by two large retrospective studies[6,7].In China,chemotherapy remains a standard first-line treatment for this patient subset,with Afatinib available only as an off-label treatment option.

关 键 词：PATIENTS HARBOR TREATMENT 

分 类 号：R734.2[医药卫生—肿瘤]